I'll let Robin comment on his situation, but we both met up in June when I attended his wedding and are both pleased with the results we have seen.
The three year results from the Campath Phase II were announced in October 2007. The key points on Campath's efficacy were:
Dr. Compston summarized the main benefits seen in the CAMMS223 trial as: (1) alemtuzumab is significantly more effective than high-dose IFN beta-1a at suppressing relapses and slowing accumulation of disability; (2) disability increases over time with IFNbeta-1a treatment, while it improves with alemtuzumab; (3) no clear dose response can be demonstrated; (4) the outcomes appear to be improved after three cycles of treatment; and (5) the main adverse effects are secondary autoimmunity.
"So the important message is, if you take alemtuzumab,  years later, your disability is [still] less than it was at the outset, so patients coming onto our trial actually improve if they take alemtuzumab," Dr. Compston said.
"We would hope that this will become a treatment for people who have early MS with signs of an aggressive disease but who aren't disabled, so we could prevent them getting disabled," he added.
My disability score has reduced to 2 when I was last assessed in November. I have had no relapses since my first infusion (end of November 2006). I do get tight calves and stiff ankles, but this comes and goes. Some days I forget I have MS - which is a real blessing.
What this means for the long-term - who knows. But the people in Cambridge are monitoring all recipients closely. More data on the Phase II trial is to be presented in April 2008.
The Phase III trials results will not be available until 2010 and I imagine that, if positive, Campath will be available in 2011. But by then, there will also be results from a range of other treatments, such as oral drugs. FTY 720 may show good results in terms of reducing relapses and may encourgae some repair. We can only work with what we have available now, balanced with an individual's assessment of the risk they are prepared to accept from a treatment.
2008 could be another very interesting year with results expected from several trials.